文献速递复苏、休克与脓毒症消化、代谢与肾脏急症重症综合管理与镇静镇痛

重症新型冠状病毒肺炎患者血电解质与预后的关系

[Relationship between blood electrolytes and prognosis of patients with severe coronavirus disease 2019].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2022-01-01
一句话结论重症COVID-19患者入ICU时血钾、血钙及钾钙比值与预后相关,钾钙比值是死亡的独立危险因素,比值越高预后越差。

该研究收集2020年1月21日至3月4日上海援鄂医疗队入驻武汉第三医院ICU收治的110例重症COVID-19患者临床资料,按血钾、血钙水平及钾钙比值分组,用Kaplan-Meier生存曲线、限制性立方样条图和Cox回归模型分析血电解质与预后的关系。结果显示死亡组血钾高于生存组、血钙低于生存组;血钾>4.2 mmol/L组预后较血钾<3.8 mmol/L组和3.8-4.2 mmol/L组差,血钙>2.23 mmol/L组预后优于血钙<2.03 mmol/L组和2.03-2.23 mmol/L组;钾钙比值>1.9组生存率最低,校正其他指标后钾钙比值仍与预后相关(HR=4.85,P=0.033)。提示入ICU时血钾、血钙及钾钙比值与重症COVID-19患者预后相关,钾钙比值是死亡的独立危险因素。

要点

  • 110例重症COVID-19患者中死亡32例、生存78例;死亡组血钾4.25(3.80,4.65)mmol/L高于生存组3.90(3.60,4.20)mmol/L(P<0.05),血钙2.00±0.14 mmol/L低于生存组2.19±0.18 mmol/L(P<0.05)。
  • 血钾>4.2 mmol/L组预后较血钾<3.8 mmol/L组和3.8-4.2 mmol/L组差(P=0.011);血钙>2.23 mmol/L组预后优于血钙<2.03 mmol/L组和2.03-2.23 mmol/L组,血钙越低预后越差(P=0.000 15)。
  • 钾钙比值>1.9组较<1.7组和1.7-1.9组血钾更高、机械通气比例更高、血钙更低、生存比例更低、ICU入住时间更长;该组生存率最低(P<0.000 1),<1.7组与1.7-1.9组生存差异无统计学意义。
  • 校正年龄和性别后,模型1(单一血钾或血钙)血钾HR=2.08、血钙HR=0.01,模型2(模型1加年龄和性别)血钾HR=1.98、血钙HR=0.01,均与预后显著相关(均P<0.05)。
  • 校正其他指标后钾钙比值仍与预后相关(HR=4.85,P=0.033),是死亡的独立危险因素;校正年龄和性别后的限制性立方样条图显示钾钙比值>1.8组HR值>1。

适用人群与场景

  • 2020年1月21日至3月4日由上海援鄂医疗队收治于武汉第三医院ICU的重症COVID-19患者,最终纳入110例。

诊断标准与关键阈值

  • 按血钾分组:<3.8 mmol/L组、3.8-4.2 mmol/L组、>4.2 mmol/L组。
  • 按血钙分组:<2.03 mmol/L组、2.03-2.23 mmol/L组、>2.23 mmol/L组。
  • 按血钾/钙比值分组:<1.7组、1.7-1.9组、>1.9组。

研究设计与关键结果

  • 研究类型为纳入110例重症COVID-19患者的临床资料分析,78例生存、32例死亡。
  • 死亡组较生存组血钾更高[4.25(3.80,4.65)mmol/L vs. 3.90(3.60,4.20)mmol/L,P<0.05]、血钙更低(2.00±0.14 mmol/L vs. 2.19±0.18 mmol/L,P<0.05)。
  • Kaplan-Meier生存曲线:血钾>4.2 mmol/L组预后较血钾<3.8 mmol/L组和3.8-4.2 mmol/L组差(P=0.011);血钙>2.23 mmol/L组预后优于血钙<2.03 mmol/L组和2.03-2.23 mmol/L组,血钙较低组预后更差(P=0.000 15)。
  • Cox回归:模型1(单一血钾或血钙)血钾HR=2.08、血钙HR=0.01;模型2(模型1加年龄和性别)血钾HR=1.98、血钙HR=0.01,均与预后显著相关(均P<0.05)。
  • 钾钙比值>1.9组较<1.7组和1.7-1.9组血钾更高、机械通气比例更高、血钙更低、生存比例更低、ICU入住时间更长。
  • Kaplan-Meier生存曲线:钾钙比值>1.9组生存率最低(P<0.000 1),<1.7组与1.7-1.9组生存差异无统计学意义。
  • 校正年龄和性别后的限制性立方样条图显示钾钙比值>1.8组HR值>1。
  • 校正其他指标后Cox回归显示钾钙比值仍与预后相关(HR=4.85,P=0.033)。

证据类型、等级与局限

  • 证据类型:基于110例重症COVID-19患者临床资料的队列分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为入ICU时血钾、血钙及钾钙比值与重症COVID-19患者预后相关,钾钙比值是死亡的独立危险因素,比值越高预后越差。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To analyze the relationship between blood electrolytes and the prognosis of patients with severe coronavirus disease 2019 (COVID-19) and to provide assistance for clinical decision-making.

METHODS: The clinical data of patients with severe COVID-19 admitted to intensive care unit (ICU) of the Wuhan Third Hospital by the Shanghai aid-Hubei medical team from January 21 to March 4, 2020 were collected. Excluding ineligible patients, 110 patients were finally enrolled. The patients' gender, age, temperature, heart rate, systolic and diastolic blood pressure, clinical symptoms at admission, time of symptom onset, duration of fever, and relevant indicators at admission to ICU (including blood potassium, chloride, sodium, calcium, phosphorus, and magnesium, etc.) and prognosis were analyzed. The patients were grouped by blood potassium or calcium levels or blood potassium/calcium ratio. The Kaplan-Meier survival curves were used to analyze the survival of patients in each group. The relationship between the potassium/calcium ratio and the prognosis was analyzed using restricted cubic spline plots. The relationship between each index in the different models and the prognosis was analyzed using Cox regression models.

RESULTS: Among 110 severe COVID-19 patients, 78 cases survived, and 32 cases died. Compared with the surviving group, patients in the death group had higher blood potassium levels [mmol/L: 4.25 (3.80, 4.65) vs. 3.90 (3.60, 4.20), P < 0.05] and lower blood calcium levels (mmol/L: 2.00±0.14 vs. 2.19±0.18, P < 0.05). The Kaplan-Meier survival curves showed that patients in the potassium > 4.2 mmol/L group had a worse prognosis than the potassium < 3.8 mmol/L group and the potassium 3.8-4.2 mmol/L group (P = 0.011), patients in the calcium > 2.23 mmol/L group had a better prognosis than the calcium < 2.03 mmol/L group and the calcium 2.03-2.23 mmol/L group, and the lower calcium group had a worse prognosis (P = 0.000 15). Cox regression analysis showed that the hazard ratio (HR) of blood potassium and calcium were 2.08 and 0.01, respectively, in model 1 (single blood potassium or calcium) and in model 2 (model 1 plus age and gender), the HR of blood potassium and calcium were 1.98 and 0.01 respectively, which were significantly associated with patient prognosis (all P < 0.05). Patients in the group with the potassium/calcium ratio > 1.9 had higher blood potassium levels and a higher proportion of mechanical ventilation, lower calcium levels and lower proportion of survival, and longer time of ICU admission compared with the groups with the potassium/calcium ratio < 1.7 and 1.7-1.9. The Kaplan-Meier survival curves showed that the survival rate of the potassium/calcium ratio > 1.9 group was the lowest (P < 0.000 1), and there was no statistically significant difference in survival between the potassium/calcium ratio < 1.7 group and the potassium/calcium ratio 1.7-1.9 group. A restricted cubic spline plot corrected for age and gender showed that patients in the potassium/calcium ratio > 1.8 group had HR values > 1. Cox regression analysis corrected for other indicators showed that the potassium/calcium ratio was still associated with patient prognosis (HR = 4.85, P = 0.033).

CONCLUSION: Blood potassium, calcium, and the potassium/calcium ratio at ICU admission are related to the prognosis of patients with severe COVID-19, and the potassium/calcium ratio is an independent risk factor for the death of patients. The higher the potassium/calcium ratio, the worse the prognosis of patients.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Chen D, Zhao Q, Xie Y, et al. [Relationship between blood electrolytes and prognosis of patients with severe coronavirus disease 2019]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 35728852. doi:10.3760/cma.j.cn121430-20211013-01474

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。